UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April
24, 2025
September
30, 2024
SRx
Health Solutions, Inc.
(Exact
name of Registrant as Specified in its Charter)
Delaware |
|
001-40477 |
|
83-4284557 |
(State
or other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
12400
Race Track Road
Tampa, Florida 33626
(Address
of Principal Executive Offices) (Zip Code)
(Registrant’s
Telephone Number, Including Area Code):(212) 896-1254
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.001 par value share |
|
SRXH |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
On
April 24, 2025 (the “Closing Date”), SRx Health Solutions, Inc., a Delaware corporation (f/k/a Better Choice Company, Inc.)
(the “Company” or the “Registrant” or “we”, “us” or “our”) announced that
it closed the business combination (the “Business Combination”) by and among the Company, 1000994476 Ontario Inc., an Ontario
corporation (“AcquireCo”), 1000994085 Ontario Inc., an Ontario Corporation (“CallCo”) and SRx Health Solutions
(Canada), Inc., an Ontario corporation (f/k/a SRx Health Solutions, Inc.) (“SRx Canada”), whereby the Company acquired SRx
Canada pursuant to the terms of an Arrangement Agreement and Plan of Arrangement entered into on September 2, 2024, by and among the
Company, AcquireCo, CallCo and SRx Canada (the “Arrangement Agreement”). Pursuant to the Arrangement Agreement, on the Closing
Date, AcquireCo, an indirect wholly-owned subsidiary of the Company, merged with and into SRx Canada, with SRx Canada remaining as the
surviving entity.
The
Company filed a Current Report on Form 8-K on April 24, 2025 (the “Initial Report”) in which the Company disclosed, among
other information, its intention to file the financial statements required by Item 9.01(a) and the pro forma financial information required
by Item 9.01(b) as part of an amendment to the Initial Report no later than 71 calendar days after the required filing date of the Initial
Report. This Current Report on Form 8-K/A amends the Initial Report to include certain financial statements of the Company and certain
pro forma financial information as required by Item 9.01, which are filed as exhibits hereto and are incorporated herein by reference.
No disclosure of the text of Item 1.01, Item 2.01, Item 5.01, Item 5.02, Item 5.03, Item 8.01 or Item 9.01(d) of the Initial Report was
changed as a result of this Current Report on Form 8-K/A except for the addition of the exhibits listed in Item 9.01(d) of this Current
Report on Form 8-K/A.
Item
9.01. Financial Statements and Exhibits.
(a) |
Financial Statements of Businesses
Acquired. |
SRx
Canada’s consolidated financial statements for the years ended September 30, 2024 and 2023 and related notes are filed as Exhibit
99.1 to this Current Report on Form 8-K/A and are incorporated herein by reference.
SRx
Canada’s unaudited condensed consolidated financial statements for the three and six months ended March 31, 2025 and 2024
and related notes are filed as Exhibit 99.2 to this Current Report on Form 8-K/A and are incorporated herein by reference.
(b) |
Pro Forma Financial Information. |
The
unaudited pro forma condensed combined financial information of the Company, giving effect to the Business Combination, is filed as Exhibit
99.3 to this Current Report on Form 8-K/A and is incorporated herein by reference.
The
unaudited pro forma condensed combined financial information and the accompanying notes included in this Current Report on Form 8-K/A
has been presented for informational purposes only, as required by the disclosure requirements of Form 8-K, and is not necessarily indicative
of the actual financial position or results of operations that the Company would have realized had the companies been combined as of
the dates or during the periods presented, nor is it intended to be indicative of any anticipated combined financial position or future
results of operations that the Company may achieve after the Business Combination.
The
following exhibits are included as part of this Current Report on Form 8-K/A:
Exhibit
No. |
|
Description |
|
|
|
23.1 |
|
Consent
of MNP LLP, independent auditors of SRx Health Solutions (Canada), Inc. (f/k/a SRx Health Solutions, Inc.). |
99.1 |
|
SRx Canada’s consolidated financial statements for the years ended September 30, 2024 and 2023 and related notes. |
99.2 |
|
SRx
Canada’s unaudited condensed consolidated financial statements for the three and six months ended March 31, 2025 and
March 31, 2024 and related notes. |
99.3 |
|
Unaudited pro forma condensed combined financial information and related notes. |
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
July
11, 2025 |
SRx Health Solutions, Inc. |
|
|
|
|
By: |
/s/
Carolina Martinez |
|
Name: |
Carolina
Martinez |
|
Title: |
Chief
Financial Officer |